Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285074 | 1.00 | MEN1 (0.47) | MEN1KMT2AUGT2B7ALDH1A1MAPK1 | |
| SCHEMBL343476 | 1.00 | MEN1 (0.47) | MEN1KMT2AUGT2B7ALDH1A1MAPK1 | |
| SCHEMBL29626738 | 1.00 | MEN1 (0.47) | MEN1KMT2AUGT2B7ALDH1A1MAPK1 | |
| SCHEMBL1812811 | 0.84 | SLC6A2 (0.51) | ALDH1A1MAPK1IDO1TDO2CYP3A4 | |
| SCHEMBL9331663 | 0.83 | UGT2B7 (0.56) | MEN1KMT2AUGT2B7ALDH1A1CYP3A4 | |
| SCHEMBL2812852 | 0.83 | UGT2B7 (0.56) | MEN1KMT2AUGT2B7ALDH1A1CYP3A4 | |
| SCHEMBL9331659 | 0.83 | UGT2B7 (0.56) | MEN1KMT2AUGT2B7ALDH1A1CYP3A4 | |
| SCHEMBL9334664 | 0.83 | UGT2B7 (0.56) | MEN1KMT2AUGT2B7ALDH1A1CYP3A4 | |
| SCHEMBL13963168 | 0.83 | CYP3A4 (0.47) | ALDH1A1MAPK1IDO1TDO2CYP3A4 | |
| SCHEMBL11216092 | 0.83 | ALDH1A1 (0.42) | ALDH1A1MAPK1IDO1TDO2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-11377425-B1 | Small molecule modulators of IL-17 | LEO PHARMA A/S (DK) | 2022-07-05 | — | — | US | disclosed |
| US-11377425-B1 | Small molecule modulators of IL-17 | LEO PHARMA A/S (DK) | 2022-07-05 | — | — | US | disclosed |
| US-11261195-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210214370-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2021-07-15 | — | — | US | disclosed |
| CN-108101741-B | Method for synthesizing chiral alcohol by alkyne hydration/asymmetric hydrogenation tandem | 三峡大学 | 2021-06-29 | — | — | CN | disclosed |
| US-10894795-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-7642073-B2 | Using mixture comprising modified alcohol dehydrogenase, ammonia, nicotinamide and 2-ketoacid to generate preferential amino acids | CODEXIS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| CN-100398626-C | Method for increasing helical twist rate, optically active compound, liquid crystal composition containing the same, and liquid crystal display element | DAINIPPON INK & CHEMICALS (JP) | 2008-07-02 | — | — | CN | disclosed |
| US-20080076162-A1 | Using mixture comprising modified alcohol dehydrogenase, ammonia, nicotinamide and 2-ketoacid to generate preferential amino acids | BIOCATALYTICS, INC. | 2008-03-27 | — | — | US | disclosed |
| US-7202070-B2 | Generating phenylalanine and leucine using mutant enzymatic polypeptide; generate mutant enzyme, aminate ketoacid, recover amino acids | BIOCATALYTICS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7108896-B2 | Method of increasing helical twisting power, optically active compound, liquid crystal compostion containing the same, and liquid crystal display device | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2006-09-19 | — | — | US | disclosed |
| CN-1174103-C | Process for preparing chiral substituted arylepoxyethane compounds and its biol by selective splitting of Aspergillus niger | 中国科学院上海有机化学研究所 | 2004-11-03 | — | — | CN | disclosed |
| CN-1495246-A | Method for increasing helical twist rate, optically active compound, liquid crystal composition containing the same, and liquid crystal display element | 大日本油墨化学工业株式会社 | 2004-05-12 | — | — | CN | disclosed |
| US-20040021128-A1 | Method of increasing helical twisting power, optically active compound, liquid crystal composition containing the same, and liquid crystal display device | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2004-02-05 | — | — | US | disclosed |
| US-20020061564-A1 | Generating phenylalanine and leucine using mutant enzymatic polypeptide; generate mutant enzyme, aminate ketoacid, recover amino acids | CODEXIS, INC. | 2002-05-23 | — | — | US | disclosed |
| WO-2002036742-A2 | METHOD FOR CHEMICAL TRANSFORMATION USING A MUTATED ENZYME | BIOCATALYTICS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261195-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | MEN1 3638/4885KMT2A 373/4885UGT2B7 3435/4885 |
| US-20210214370-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | MEN1 3670/4885KMT2A 370/4885UGT2B7 3492/4885 |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | MEN1 3670/4885KMT2A 370/4885UGT2B7 3492/4885 |
| US-11377425-B1 | Small molecule modulators of IL-17 | IL17A, IL15, IL2 | MEN1 2191/4885KMT2A 3095/4885UGT2B7 146/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | MEN1 3638/4885KMT2A 373/4885UGT2B7 3435/4885 |
| US-10894795-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | MEN1 3670/4885KMT2A 370/4885UGT2B7 3492/4885 |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | MEN1 3638/4885KMT2A 373/4885UGT2B7 3435/4885 |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | MEN1 3638/4885KMT2A 373/4885UGT2B7 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.